3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

Generic drugmakers are facing headwinds from pricing pressure, potential tariffs, and the "most-favored-nation" pricing model, impacting revenues and profitability; branded drugmakers are better positioned to withstand these pressures. Despite industry challenges, Sandoz (SDZNY), Teva Pharmaceuticals (TEVA), and Viatris (VTRS) are highlighted as companies well-positioned to navigate these headwinds due to their global scale, diversified portfolios, and strategic emphasis on complex and branded generics. The Zacks Medical – Generic Drugs industry has underperformed the broader market year-to-date, declining approximately 10%.

Analysis

The generic drug manufacturing sector is currently navigating significant headwinds, including intense pricing competition, the looming threat of U.S. pharmaceutical import tariffs, and potential disruptions from proposed 'most-favored-nation' pricing models, all of which exert pressure on revenues and already tight margins. This challenging environment is reflected in the Zacks Medical – Generic Drugs industry's performance, which has declined approximately 10% year-to-date, substantially underperforming both the broader Zacks Medical sector's 4% fall and the S&P 500's 2% dip, and its current Zacks Industry Rank in the bottom 25% of industries signals gloomy prospects. The industry's forward 12-month P/E ratio of 10.40X also trades at a significant discount to the S&P 500 (21.96X) and the Zacks Medical sector (19.13X). Despite these overarching concerns, certain companies like Sandoz (SDZNY), Teva (TEVA), and Viatris (VTRS), all holding a Zacks Rank #3 (Hold), are identified as potentially better equipped due to global scale, diversified portfolios emphasizing complex/branded generics, and cost optimization. Sandoz reported a 3% (ex-FX) increase in Q1 2025 net sales to $2.48 billion, driven by biosimilars, expects mid-single-digit 2025 sales growth with a core EBITDA margin around 21%, and saw its 2025 EPS consensus estimate rise to $3.17, contributing to a 51% stock appreciation over the past year. Teva, with a 7% U.S. generic market share and significant ex-U.S. revenues, leverages its U.S. manufacturing and a robust biosimilar pipeline (seven U.S., four European launches expected 2025-2027), though its 2025 EPS consensus estimate recently dipped to $2.51. Viatris has benefited from recent generic launches but faces an FDA import alert on its Indore facility; its stock declined 17% over the past year, while its 2025 EPS consensus estimate slightly increased to $2.25.

Key Decisions for Investors

• Investors should approach the generic drug sector with caution due to significant headwinds such as pricing pressures, potential U.S. import tariffs, and regulatory uncertainties impacting profitability, reflected in the industry's 10% year-to-date decline and low Zacks Industry Rank.
• Focus on companies demonstrating resilience through strategic advantages such as Sandoz (SDZNY), with its strong biosimilar-driven growth (Q1 2025 sales +3% ex-FX, stock +51% past year, EPS estimate up), and Teva (TEVA), leveraging its global scale, U.S. manufacturing footprint, and extensive biosimilar pipeline, despite a recent minor dip in its 2025 EPS consensus.
• Monitor critical developments including the successful launch and market uptake of new biosimilars for blockbuster drugs, the resolution of Viatris's (VTRS) FDA import alert for its Indore facility, and any definitive U.S. policy changes regarding pharmaceutical tariffs or pricing models.
• Evaluate individual generic drugmakers based on their ability to generate value from complex generics and biosimilars, their geographic revenue diversification, and the effectiveness of their cost optimization programs, as these will be key differentiators in the current challenging market.